Can COVID-19 have a clinically significant effect on drug metabolism?

Felicia Ceban; Mehala Subramaniapillai; Joshua D Rosenblat; Rodrigo B Mansur; Roger S McIntyre

doi:10.1080/14740338.2023.2172158

Can COVID-19 have a clinically significant effect on drug metabolism?

Expert Opin Drug Saf. 2023 Jan;22(1):1-3. doi: 10.1080/14740338.2023.2172158. Epub 2023 Feb 5.

Authors

Felicia Ceban^{1

2

3}, Mehala Subramaniapillai¹, Joshua D Rosenblat^{1

4

5}, Rodrigo B Mansur^{1

4}, Roger S McIntyre^{1

3

4

5}

Affiliations

¹ Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
² Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
³ Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
⁴ Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁵ Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.

PMID: 36691834
DOI: 10.1080/14740338.2023.2172158

No abstract available

Keywords: Bipolar disorder; COVID-19; CYP450; SARS-CoV-2; cognition; cytokines; depression; drug metabolism; inflammation; liver; long COVID; mood disorders; pharmacokinetics; pharmacology; pharmacovigilance; population health; post-COVID-19 condition; prevention; tolerability; treatment; vaccination.

Publication types

Editorial

MeSH terms

COVID-19*
Humans
Vaccination